Trial Profile

Tesamorelin Effects on Liver Fat and Histology in HIV: A Collaborative UO1 Grant

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 02 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tesamorelin (Primary)
Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
Focus Therapeutic Use

Most Recent Events

13 Oct 2023 According to a Theratechnologies media release, a retrospective sub analysis from this study presented as poster in at ID Week 2023 in Boston, Mass.
13 Oct 2023 Results presented in the Theratechnologies Media Release.
14 Apr 2021 Results assessing effects of a GH releasing hormone analog, tesamorelin, on circulating immune markers and liver tissue in people with HIV and NAFLD, published in the Clinical Infectious Diseases

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com